ClinicalTrials.gg
Not yet recruitingNCT07536282Updated Apr 17, 2026

Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

A Phase 1/2 interventional study of NWRD09 and Placebo in Persistent HPV16 Infection, sponsored by Newish Biotech (Wuxi) Co., Ltd.. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Newish Biotech (Wuxi) Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

This is a two-part, phase I/IIa study, intended to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09 in female participants with persistent HPV16 infection, and to determine the MTD, and/or RP2D of NWRD09.

02

Conditions studied

  • Persistent HPV16 Infection

Keywords

  • persistent HPV16 infection
  • therapeutic mRNA vaccine
03

In context

Lead sponsor

Newish Biotech (Wuxi) Co., Ltd. is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have fully understood the study, able and willing to comply with all study procedures, and voluntarily sign written ICF;
  • Female participants aged 18-60 years (inclusive) at the time of signing the ICF;
  • Persistent HPV16 infection, defined as virologically confirmed HPV16 positivity persisting for ≥ 6 months before screening (e.g., participants must provide investigator-approved evidence of HPV16 infection ≥ 6 months prior to screening and be HPV16 positive at the time of screening);
  • Participants must have a confirmed cytological results of atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion (ASC-H) or high-grade squamous intraepithelial lesion (HSIL) at the time of screening (histopathological confirmed cervical/vaginal/vulvar LSIL are acceptable but not required);
  • Satisfactory colposcopy at screening;
  • Normal major organ functions at screening;
  • Women of must have a negative serum pregnancy test result at screening. All WOCBP participants agree to voluntarily use effective , from signing the ICF to the end of the study. In addition, female participants must agree not to donate eggs during this period.

Exclusion criteria

Exclusion Criteria:

  • Histopathological confirmed high-grade cervical, vulvar, vaginal or anal intraepithelial lesions (including endocervical adenocarcinoma-in-situ [AIS]) or invasive cancer, OR cervical cytology results showing squamous cell carcinoma (SCC), atypical glandular cells (AGC), or AIS at screening;
  • Negative for HPV16 as confirmed by real-time quantitative polymerase chain reaction (RT-qPCR) at screening;
  • Comorbid infectious diseases, such as acute pelvic inflammatory disease, urinary tract infection, or other active infections requiring systemic treatment prior to the first injection;
  • Participants with unresolved vaginal/cervical conditions prior to the first injection that could affect clinical response (e.g., common sexually transmitted infections such as gonorrhoea, genital herpes, etc.);
  • Positive serological test results at screening for (HIV), treponema pallidum antibody, or virus surface antigen (HBsAg) positive; or virus antibody (HCV-Ab) positive and hepatitis C virus (HCV) ribonucleic acid (RNA) quantitative > the lower limit of the positive detection value of the study site;
  • Significant abnormalities at the screening , including > 470 msec (average of triplicate measurements corrected for heart rate using Fridericia's formula), or history/presence of clinical symptoms of cardiac diseases that is not well controlled, such as (NYHA) Class 2 or higher heart failure, unstable angina, myocardial infarction within the past 6 months, and supraventricular or ventricular arrhythmia requiring treatment or intervention;
  • Systemic use (e.g., > 10 mg/day prednisone for > 1 week) within 30 days before screening, excluding hormone replacement therapy and local/topical use (e.g., ocular, intratracheal);
  • use (> 1 week) within 30 days or 5 drug half-lives (whichever is longer) before screening (including but not limited to cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, or antilymphocyte globulin);
  • Current or planned use of disease-modifying antirheumatic drugs (DMARDs, e.g., azathioprine, cyclophosphamide, cyclosporine, methotrexate) or biologic DMARDs (e.g., infliximab, adalimumab, etanercept) during the study;
  • Received any vaccine (other than HPV prophylactic vaccines) within 8 weeks before screening or plan to receive any vaccine during the study;
  • History of therapeutic HPV vaccination.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    NWRD09

    Predefined dose groups of NWRD09

    Biological: NWRD09

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalNWRD09

    Participants will receive 4 injections of NWRD09 via IM to the lateral deltoid region of the upper arm, at D1 (W0D1), D15 (W2D1), D29 (W4D1) and D85 (W12D1)

  • BiologicalPlacebo

    Participants will receive 4 injections of Placebo via IM to the lateral deltoid region of the upper arm, at D1 (W0D1), D15 (W2D1), D29 (W4D1) and D85 (W12D1)

06

What researchers measure

Primary outcomes

  1. Incidence and severity of local and systemic adverse events (AEs).

    Adverse events (AEs) and serious adverse events (SAEs) will be monitored based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

    Time frame: Up to Week 28

Secondary outcomes

  1. Proportion of participants with clearance of HPV16

    Time frame: Weeks 16 and 28

  2. Proportion of participants with cervical cytology normal/ASC-US/LSIL

    Time frame: Week 16 and 28

  3. For participants with histopathological LSIL at baseline, proportion of participants with histopathological regression to NSIL

    Time frame: Week 28

  4. T cell responses to the separate or combined protein peptide pools of HPV16 E1, E2, E6 and E7 proteins

    Time frame: Weeks 6, 16 and 28

  5. Serum HPV16 E6/E7-specific IgG antibodies will be determined by ELISA

    Time frame: Weeks 6, 16 and 28

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 17, 2026
StartEst.
Oct 2026
Primary completionEst.
Sep 2027
CompletionEst.
Nov 2027
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07536282
Responsible party
Sponsor
First posted
Apr 17, 2026
Start date
Oct 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Apr 17, 2026

Study contacts

June Y. Hou, MD
Contact
jh3558@cumc.columbia.edu
212-305-3410

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NWRD09

Start the discussion